AI GxP validation for regulated life sciences
Industries

Built For Regulated Life Sciences

Eight industries, one AI-first playbook for validation, compliance and clinical technology.

Quick chat on WhatsAppHuman review at every gatePart 11 readyISO 9001 & 27001 certified
FDAEMAMHRAPMDACDSCOGAMP 5ICH Q921 CFR Part 11
In short

Cybroscape works across pharmaceuticals, biotechnology, medical devices, CROs, CDMOs and CRDMOs, cell and gene therapy, diagnostics, vaccines and healthcare technology. Each carries its own regulations, its own risk topology and its own decision-makers — but the standard for a defensible record is the same everywhere: traceable evidence, attributable decisions, and reasoning an inspector can follow.

Pharmaceuticals

From CMC through commercial supply, pharma runs on validated systems: SAP, LIMS, MES, SCADA, eQMS, RIM. Cybroscape gives you a CSA-native validation practice, TraceDraft for clinical documentation, and GxP Copilot for continuous validation across the estate.

Explore
Biotechnology

A growing biotech needs inspection-ready validation and clinical documentation without building a large validation department first. Cybroscape is designed for that stage: AI-drafted deliverables your people review and approve, priced for mid-sized teams.

Explore
Medical Devices

For med-device manufacturers, validation and clinical evaluation share the same DNA: traceable claims, controlled documents, and defensible audits. Cybroscape covers both — GxP Copilot for QMS / eQMS / MES validation, TraceDraft for CERs and post-market surveillance documentation.

Explore
Contract Research Organisations (CRO)

CROs live and die by writing throughput and audit posture. TraceDraft accelerates CSR, protocol, safety-narrative and medical-writing delivery with source-traceable AI; GxP Copilot keeps your validated clinical technology estate audit-ready.

Explore
CDMO & CMO

A CDMO runs one set of validated systems for many sponsors. Every client audits it, every client's process lives inside the same LIMS, MES and quality system, and every tech transfer adds recipes, methods and specifications to validated software. GxP Copilot keeps that estate validated as it changes, and our validation leads make each sponsor audit routine.

Explore
CRDMO

A CRDMO takes a molecule from discovery chemistry to commercial supply under one roof. That means research data that starts outside GxP, development data that may later support a filing, and manufacturing systems held to full GMP, all linked, all audited by sponsors, and often inspected by FDA, EMA and CDSCO in the same year.

Explore
Cell & Gene Therapy (ATMP)

In autologous cell and gene therapy every batch belongs to one patient. The systems that schedule collection, track chain of identity and custody, run manufacturing and support release are part of the therapy itself, where a mix-up is a patient-safety event rather than a deviation. We validate that estate end to end, sized to that risk.

Explore
Diagnostics

Diagnostics teams need LIMS/ELN validation, IVDR clinical performance evidence, and data-integrity discipline. Cybroscape delivers all three, plus AI validation for algorithm-driven assays.

Explore
Vaccines

Vaccine developers and manufacturers need robust CMC documentation, cold-chain data integrity, and a regulatory intelligence layer that keeps up with WHO PQ, EMA and FDA. Cybroscape supports the full lifecycle.

Explore
Life Sciences

Cybroscape is a Life Sciences technology company. We build the AI-first validation, compliance and clinical technology layer that pharma, biotech, med-device, CRO, diagnostics and vaccines operators buy from us.

Explore
Healthcare Technology

HealthTech companies need to move fast and still ship regulated products. Cybroscape provides a fit-for-purpose validation and AI-governance stack tuned for HealthTech velocity — including SaMD validation and clinical documentation for the evidence dossier.

Explore
What differs

What actually differs between industries

Three things, and they matter more than they first appear. The governing regulations differ — GMP with Annex 11 and Annex 15 for pharmaceutical manufacturing, MDR or IVDR and QSR for devices, GCP for clinical research. The risk topology differs: a sterile manufacturing line and a clinical database fail in entirely different ways and are inspected accordingly.

And the decision-makers differ. A pharma quality head, a device regulatory affairs lead and a CRO operations director are answering different questions and respond to different evidence. A vendor who speaks only one of those dialects gets a long way into the wrong conversation.

  • The governing regulations
  • The risk topology
  • The decision-makers
What stays the same

What does not differ

The standard for a defensible record. Every test traces to a numbered requirement. Every deviation has a documented resolution rather than a note saying it was accepted. Every approval is attributable to a person who could realistically have checked what they signed. Records are tamper-evident, and that can be demonstrated rather than asserted.

Inspectors in every one of these industries pull on the same threads, because those threads are where the truth about an organisation's control is found.

  • Every test traces to a requirement
  • Every deviation has a documented outcome
  • Every signature is attributable
Where validation sits
  1. 01ResearchELNLIMSData that can support a filing
  2. 02ClinicalEDCeTMFCTMSTrial records and their audit trails
  3. 03ManufacturingMESERPSCADABatch records and process control
  4. 04QualityeQMSDocument managementDeviations, CAPA and change control
  5. 05Regulatory and safetyRIMSafety databaseSubmissions and safety cases
Where validated systems sit across a typical life sciences value chain, and what an inspector looks at in each stage. Typical systems shown; your estate will differ.
Company size

Company size changes the problem more than sector does

A Series B biotech and a top-twenty manufacturer deploying the same LIMS face the same Annex 11 and Part 11 expectations. What differs is everything around the obligation: a validation department, established templates, and a QA function that has done this fifty times — none of which the smaller company has.

In practice that gap drives more of how an engagement should be scoped than the industry label does. The economics are set out in mid-market validation economics.

Scope

Assets, not just applications

Industries differ sharply in what they actually need qualified. A diagnostics laboratory is concerned with analytical instruments under USP <1058>. A sterile manufacturer is concerned with equipment under EU GMP Annex 15. A clinical research organisation is concerned with software under GAMP 5 and with clinical documents.

Forcing instruments and equipment through a software validation lifecycle produces documents that do not match what a qualification auditor expects to see — which is why the right track matters as much as the right rigour.

Software and SaaS

LIMS, MES, ERP, eQMS, RIM

Instruments

Analytical and lab instruments

Equipment

Process equipment and utilities

AI models

Models, agents and copilots

FAQ

Common questions

Prefer to talk first? Chat with us on WhatsApp or book a call with an expert.

Which industries does Cybroscape serve?

Pharmaceuticals, biotechnology, medical devices, contract research organisations, diagnostics, vaccines, healthcare technology including SaMD and digital health, and life sciences more broadly. The common thread is a regulated process where a computerised system or a clinical document has to withstand inspection.

Does validation differ between pharma and medical devices?

The lifecycle is similar; the governing regulations and the evidence a reviewer expects are not. Pharmaceutical manufacturing answers to GMP, Annex 11 and Annex 15. Medical devices answer to MDR or IVDR and QSR, with clinical evaluation and post-market surveillance obligations that have no direct pharma equivalent.

What is different about validation for a CRO?

The constraint is usually throughput rather than compliance posture. CROs run many studies across many sponsors, each with its own templates and expectations, so the pressure falls on clinical writing capacity and on demonstrating consistency across sponsors — rather than on validating a small number of manufacturing systems deeply.

Do small biotechs really need full validation?

They need validation proportionate to risk, which is not the same as a large manufacturer's package. A Series B biotech faces the same regulatory obligation without a validation department, so the answer is usually correct categorisation, leveraged supplier evidence and a lean but complete lifecycle — not a scaled-down copy of a big pharma template.

What stays the same across every industry?

That evidence must be traceable, decisions must be attributable to a person, records must be tamper-evident, and an inspector must be able to follow the reasoning. The regulations differ, the risk topology differs, the decision-makers differ — what a defensible record looks like does not.

Talk to someone who knows your industry.

Our leads have shipped inspection-ready systems in FDA, EMA, MHRA, PMDA and CDSCO environments.

  • We reply within one business day
  • We run your URS live on the call
  • You get a clear plan for your system
Chat on WhatsApp

Talk to an industry lead

Four fields. The right specialist replies within one business day.

Your details stay private. We never share them.